Symbiotec Pharmalab Q2 FY27 Earnings Call: Rs. 53 Cr Milestone Lifts Revenue 43%, Europe Deal Expands Capacity to 750 KL

Milestone-Boosted Quarter Masks Solid Underlying Growth

• Rs.280 Cr consolidated revenue, +43% YoY — Q2 FY 2026-2027 includes Rs.53 Cr of milestone revenue from the complex injectable (DCV) business; H1 FY 2026-2027 revenue grew 25% YoY.
• Rs.94 Cr EBITDA, +88% YoY — adjusted for one-time IPO expenses of Rs.3 Cr debited to P&L in the quarter (vs Rs.50 Cr in Q2 FY26); H1 FY 2026-2027 EBITDA grew 29% to Rs.140 Cr.
• Rs.52 Cr PAT, +169% YoY — flattered by the milestone recognition pulled forward from H2 FY 2026-2027 into Q2.
• Trade receivables jumped from Rs.197 Cr to Rs.268 Cr — CFO Raghavendra Ramachandran attributed the spike to milestone invoicing, with realization in the subsequent quarter and normalization expected in Q3 FY 2026-2027.
• H1 FY 2026-2027 capex of Rs.113 Cr; net debt Rs.314 Cr — as of 30 September (Q2 FY 2026-2027 end).
• FY 2026-2027 guidance maintained — ~20% revenue growth and ~25% EBITDA growth, with a range of 5 percentage points on either side.

Mid-Teens Growth on Volume and Mix; Margin Headwinds Temporary

• API revenue of Rs.227 Cr grew 16% in Q2 FY 2026-2027 — and 11% in H1, driven largely by volume growth, aided by better geography and product mix; price pressure on APIs continues across steroid and hormone verticals.
• API gross margins held above 60% — with API EBITDA margins stable at ~30% across Q2 and H1 FY 2026-2027.
• Solvent cost inflation and Iran-war-driven logistics costs — impacted gross margins by 2-3% recently in FY 2026-2027; management views this as temporary.
• 70% of the business now focused on regulated markets and large customers — management said these qualification-driven wins are sticky and the mix-led realization benefit will continue rather than being a one-quarter effect.
• Multi-year visibility on the steroid hormones API base — management guided high single-digit YoY growth (at times low double-digit) over the next several years, anchored by the top five products (progesterone, hydrocortisone, testosterone, betamethasone, methylprednisolone) and backward integration built from 2008 to 2015.
• Premarin launch still years out — API development and validation largely complete, but the partner's formulation work continues; no commercial impact expected in the coming quarters.

Fresenius Kabi Partnership Monetizes via Milestones; ANDA on Fast Track

• Rs.53 Cr first milestone invoiced and recognized in Q2 FY 2026-2027 — under the long-term agreement signed 30 September with a leading global company (referenced in Q&A as Fresenius Kabi) for two complex injectable DCV products for the US market; balance expected over subsequent quarters.
• Milestone income guided as recurring through FY 2027-2028 — consistent year-on-year (not necessarily quarter-to-quarter), with associated product sales expected to kick in around end of FY 2027-2028.
• First DCV ANDA filed with the US FDA in September 2026 — acknowledged without RTR and granted accelerated review; goal date remains July 2027, though regulatory queries may add a few months; management expects both ANDA approval and the FDA pre-approval inspection by late calendar year 2027.
• ~USD 300 million annual US market — addressed by the two initial products; three to four more products in the pipeline, and five additional 505(b)(2) products planned, with expansion expected "in next couple of years" (subject to the partner completing business due diligence, failing which Symbiotec retains freedom to sign other distributors or sell directly).
• 20 million vial facility largely contracted — majority to the September 2026 customer; significant minority reserved for products 3, 4 and 5 and geographies beyond the US, including Europe and China, where distributor discussions are active.
• Platform extensions deliberately capex-light — dual-chamber bags (proof of concept ready) and syringes await capex commitment until closer to DCV revenues; next capex announcement (bags, testosterone or syringes) expected within a quarter or two.

European Signing Ups Capacity to 750 KL; US Alt-Protein Contract in Hand

• Signed a 10-year take-or-pay agreement with a Europe-based alternative protein company — announced on the day of the Q2 FY 2026-2027 call; the entire 750 KL phase one capacity is dedicated exclusively to this customer, with "much more" capacity planned in phase two for the same customer and product.
• Customer commitment raised from 600 KL (Q1 FY 2026-2027) to 750 KL — a "significant part" of the capex will be customer-funded (exact split undisclosed for confidentiality); phase 1 requires 12-15 months to build and is slated to commence in FY 2027-2028.
• Phase 0 runs on existing 100 KL — after ~3 months of fine-tuning, production is expected ("hopefully") to begin within FY 2026-2027, though phase 0 revenue is not significant; FY 2028-2029 is guided as the best year, with a few tens of millions of dollars of standalone toll fees expected in the P&L (raw material costs a pass-through).
• US alternate protein contract: $7-8 million per year — under a 10-year take-or-pay deal with inflationary year-on-year escalation, described by management as the "tip of the iceberg"; commercial batches expected in Q1 FY 2027-2028, with the plant needing another 5-6 months and commissioning expected April-May.
• Total project cost of roughly Rs.1,000 crore for the few million litres by end of phase 2 — with the customer contributing significantly under a "skin in the game" model rather than 100% company funding; Ujjain site expanded from 32 to 72 acres after a fresh 40-acre acquisition.
• Advanced-stage discussions with ~4 biomanufacturing customers — as of Q2 FY 2026-2027 (down from 5-7 discussions cited previously); part of the 400 KL phase 0 capacity is deliberately retained for scale-ups/trials with prospective customers, forgoing near-term revenue.
• Management declined comment on competitor Liberation Industries — reaffirming only the legally binding 10-year take-or-pay agreement on multi-million-litre capacity; the analyst cited a 25 million capex need for Liberation (currency unspecified, not confirmed by management).

Insulin Revenue Slips to Mid FY 2027-2028; Capacity Held Back for GLP-1s

• Insulin revenue start pushed from Q1 FY 2027-2028 to mid FY 2027-2028 — a couple of months' project delay after a newly hired biologics expert made changes for evolving regulatory standards; validation batches expected in Q4 FY 2026-2027 under the 5-year take-or-pay contract.
• Capex on the insulin unit a little over Rs.100 Cr — the "seven-star" drug substance facility is built to global standards and will initially supply the Indian partner for the Indian market before pursuing regulated-market business.
• Only ~50% of the 14 KL insulin capacity allocated to the Indian customer — who was willing to occupy 100% and sign extended terms; management retains capacity for GLP-1s and insulin analogs (glargine, aspart, degludec in future), noting insulin demand has "gone over the roof" while drug-substance capability remains scarce.
• Entering semaglutide (GLP-1) with customer traction on the drug substance side — via microbial fermentation; mammalian capability not yet in place, with MABs "too early to talk about."
• Classical fermentation APIs: 2 products commercialized for the Indian market — using existing Pithampur SEZ capacity, with DMFs/CPs in filing process; 6 more developed but not yet at validation scale; classical fermentation is a 2-3 year build before regulated-market entry and before synthetic biology-based proprietary products (≈FY 2029-2030).
• Vegan vitamin D3 plant completion expected by end of FY 2026-2027 — non-pharma sales to begin early FY 2027-2028; pharma-grade D3 may need about another year of qualification (≈FY 2028-2029); pricing strategy undecided, with vegan D3 currently commanding 3-4x the price of animal-derived D3.

Rs.1,000+ Cr Deployed; Execution and Commissioning Now the Focus

• Over Rs.1,000 Cr invested in the new verticals to date — with focus now shifting to commissioning and execution; the fermentation CDMO site currently has 400 KL of capacity, designed to expand multiple-fold in phases as contracts are signed.
• Corporate-level capex of Rs.200-300 Cr every year committed from FY 2026-2027 onward — funded by plowing back operating surplus as EBITDA improves.
• Biomanufacturing margin framework: nothing less than 30% ROC — with 30-40% EBITDA margins and 70-80% gross margins expected, varying by product, customer and geography (period unspecified).
• Management claims a cost USP on unit economics — Western-world capex is typically 2x per its understanding, and Symbiotec's USP is taking products from innovation to EBITDA-positive projections within 18 months (period unspecified); capital and operating cost per unit described as among the most competitive in the world today.
• Partner due diligence as de-risking — both the US and European alternative-protein partners are described as "premium startups" (the European partner an offshoot of two major European MNCs, 50% MNC / 50% venture capital owned) whose technology should allow them to become profitable within the next 18 months using Symbiotec's unit economics.
• Regulatory record supports the platform — 4 major regulatory inspections completed over the last 6 months; EIR received from the US FDA for both Rao and Pithampur SEZ facilities, plus EU GMP certification for both sites.
• Management to update investors between now and the Q3 FY 2026-2027 call — CMD Anil Satvani said Symbiotec remains excited not just for its base API business, but also its injectables and unique fermentation CDMO opportunities, as more information becomes available.